Rhinitis

• EMA approval · 2026-06-08
  EMA Authorised: Xolair (omalizumab) — Novartis Europharm Limited

  EMA has authorised Xolair (omalizumab) for indications including asthma, urticaria, and rhinitis, under the MAH Novartis Europharm Limited.

• EMA approval · 2025-05-28
  EMA Authorised: Xolair (omalizumab) — Novartis Europharm Limited

  The European Medicines Agency authorised Xolair (omalizumab) for asthma, urticaria, and rhinitis with Novartis Europharm Limited as the mark…

• FDA approval · 2025-01-27
  FDA Approved: IPRATROPIUM BROMIDE — Original Application (Lupin Pharmaceuticals, Inc.)

  FDA approves Lupin Pharmaceuticals' original application for ipratropium bromide, a generic formulation of the anticholinergic bronchodilato…

• FDA approval · 2024-11-15
  FDA Approved: IPRATROPIUM BROMIDE — Original Application (Advagen Pharma Ltd)

  FDA approved the original application for ipratropium bromide from Advagen Pharma Ltd, granting a generic approval.

• FDA approval · 2022-08-16
  FDA Approved: IPRATROPIUM BROMIDE — Original Application (Amneal Pharmaceuticals NY LLC)

  FDA approved Amneal Pharmaceuticals NY LLC's generic ipratropium bromide as an Original Application (ANDA). It is indicated for COPD-related…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2020-11-13
  FDA Approved: PHENYLEPHRINE HYDROCHLORIDE — Original Application (Eugia US LLC)

  FDA approved the original application for Phenylephrine Hydrochloride from Eugia US LLC (a generic drug product).

• FDA approval · 2011-05-10
  FDA Approved: IPRATROPIUM BROMIDE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)

  The FDA approved a supplemental application for ipratropium bromide by Hikma Pharmaceuticals USA Inc. under ANDA 076664, updating an already…